Aspiriant LLC’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.12M | Buy |
9,735
+293
| +3% | +$65K | 0.06% | 105 |
|
|
2025
Q4 | $2.16M | Buy |
9,442
+207
| +2% | +$47.2K | 0.06% | 104 |
|
|
2025
Q3 | $2.14M | Buy |
9,235
+839
| +10% | +$171K | 0.07% | 97 |
|
|
2025
Q2 | $1.56M | Sell |
8,396
-107
| -1% | -$19.9K | 0.05% | 119 |
|
|
2025
Q1 | $1.78M | Sell |
8,503
-274
| -3% | -$53.3K | 0.06% | 99 |
|
|
2024
Q4 | $1.56M | Buy |
8,777
+412
| +5% | +$75.7K | 0.06% | 111 |
|
|
2024
Q3 | $1.65M | Sell |
8,365
-133
| -2% | -$24.8K | 0.06% | 106 |
|
|
2024
Q2 | $1.46M | Sell |
8,498
-767
| -8% | -$127K | 0.06% | 104 |
|
|
2024
Q1 | $1.69M | Buy |
9,265
+260
| +3% | +$44.8K | 0.07% | 106 |
|
|
2023
Q4 | $1.4M | Sell |
9,005
-216
| -2% | -$31.5K | 0.06% | 116 |
|
|
2023
Q3 | $1.37M | Sell |
9,221
-26
| -0.3% | -$3.82K | 0.07% | 111 |
|
|
2023
Q2 | $1.25M | Buy |
9,247
+379
| +4% | +$55.6K | 0.06% | 114 |
|
|
2023
Q1 | $1.41M | Buy |
8,868
+384
| +5% | +$58.7K | 0.07% | 101 |
|
|
2022
Q4 | $1.37M | Buy |
8,484
+502
| +6% | +$77K | 0.07% | 103 |
|
|
2022
Q3 | $1.07M | Sell |
7,982
-8,632
| -52% | -$1.24M | 0.05% | 114 |
|
|
2022
Q2 | $2.54M | Buy |
16,614
+55
| +0.3% | +$8.4K | 0.12% | 74 |
|
|
2022
Q1 | $2.68M | Buy |
16,559
+8,999
| +119% | +$1.31M | 0.15% | 69 |
|
|
2021
Q4 | $1.02M | Buy |
7,560
+227
| +3% | +$26.8K | 0.05% | 131 |
|
|
2021
Q3 | $791K | Sell |
7,333
-6
| -0.1% | -$686 | 0.05% | 133 |
|
|
2021
Q2 | $827K | Sell |
7,339
-74
| -1% | -$8.33K | 0.05% | 126 |
|
|
2021
Q1 | $801K | Buy |
7,413
+768
| +12% | +$82.1K | 0.05% | 120 |
|
|
2020
Q4 | $710K | Buy |
6,645
+169
| +3% | +$16.2K | 0.05% | 130 |
|
|
2020
Q3 | $566K | Sell |
6,476
-5
| -0.1% | -$471 | 0.04% | 143 |
|
|
2020
Q2 | $636K | Sell |
6,481
-74
| -1% | -$6.51K | 0.06% | 116 |
|
|
2020
Q1 | $499K | Buy |
6,555
+1,176
| +22% | +$100K | 0.05% | 126 |
|
|
2019
Q4 | $475K | Sell |
5,379
-264
| -5% | -$21.9K | 0.04% | 142 |
|
|
2019
Q3 | $428K | Buy |
5,643
+1,970
| +54% | +$135K | 0.04% | 158 |
|
|
2019
Q2 | $268K | Hold |
3,673
| – | – | 0.02% | 193 |
|
|
2019
Q1 | $295K | Sell |
3,673
-1,988
| -35% | -$163K | 0.02% | 185 |
|
|
2018
Q4 | $521K | Sell |
5,661
-173
| -3% | -$15.2K | 0.04% | 138 |
|
|
2018
Q3 | $552K | Sell |
5,834
-651
| -10% | -$61.7K | 0.05% | 148 |
|
|
2018
Q2 | $601K | Buy |
6,485
+45
| +0.7% | +$4.39K | 0.05% | 144 |
|
|
2018
Q1 | $610K | Buy |
+6,440
| New | +$707K | 0.05% | 139 |
|
|
2017
Q4 | – | Sell |
-4,262
| Closed | -$379K | – | 83 |
|
|
2017
Q3 | $379K | Sell |
4,262
-184
| -4% | -$14K | 0.03% | 151 |
|
|
2017
Q2 | $322K | Buy |
+4,446
| New | +$299K | 0.03% | 169 |
|
|
2016
Q3 | – | Sell |
-3,905
| Closed | -$261K | – | 183 |
|
|
2016
Q2 | $261K | Buy |
+3,905
| New | +$238K | 0.02% | 164 |
|
Other funds holding ABBV
VCM
VPM
Aspiriant LLC's ABBV Position: Q1 2026 in Review
Aspiriant LLC increased its AbbVie (ABBV) stake by 3.1% in Q1 2026, buying an estimated $65K and bringing the position to 9,735 shares worth $2.12M. The position accounts for 0.06% of the portfolio, ranked #105.
Aspiriant LLC first reported a position in ABBV in Q2 2016 and has held it in 36 quarters since. The position peaked at $2.68M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Aspiriant LLC held 9,735 shares of AbbVie worth $2.12M as of Q1 2026.
- Aspiriant LLC bought 293 AbbVie shares in Q1 2026, an estimated $65K.
- AbbVie made up 0.06% of Aspiriant LLC's portfolio in Q1 2026, its #105 holding.
- Aspiriant LLC first reported a position in AbbVie in Q2 2016 and has held it in 36 quarters since.
- Aspiriant LLC's AbbVie position peaked at $2.68M in Q1 2022.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.